R-Pharm continues to dominate in segment of public procurements in Russia

8 May 2018

R-Pharm, one of Russia’s leading drugmakers, has won the 1 billion roubles (~$16 million) tender for the supplies of its teriflunomide drug for state needs, according to the company, reports The Pharma Letter’s local correspondent.

The tender was conducted without other bidders, which again sparks concerns of some Russian analysts of the affiliation of the company with the Russian Ministry of Health.

Teriflunomide, the active ingredient of French pharma major Sanofi’s (Euronext: SAN) Aubagio, is a drug, used to treat multiple sclerosis. This is the only new drug included in the program of seven high-cost nosologies, a state program in Russia that involves purchases of the most expensive drugs for state needs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK